Kenneth Galbraith, Chair & CEO at Zymeworks Inc. (ZYME), sold 108,686 shares at $25.10 ($2.7M) on 2026-01-05, disclosed to the SEC on 2026-01-05.
Open-market sale of $2.7M ZYME by Chair & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.10 | 22,657 | $569K | 20.8% |
| 2 | $25.10 | 31,686 | $795K | 29.2% |
| 3 | $25.10 | 22,657 | $569K | 20.8% |
| 4 | $25.10 | 31,686 | $795K | 29.2% |
| Total | $25.10 avg | 108,686 | $2.7M | 100% |
| Filing → |
| ZYME | SELL | 2025-01-06 | $1.7M | — | Filing → |
| ZYME | SELL | 2024-01-08 | $516K | — | Filing → |
| MGNX | SELL | 2020-09-10 | $1.1M | — | Filing → |